Mitochondrial disorders manifest enormous genetic and clinical heterogeneity - they can appear at any age, present with various phenotypes affecting any organ, and display any mode of inheritance. What mitochondrial diseases do have in common, is impairment of respiratory chain activity, which is responsible for more than 90% of energy production within cells. While diagnostics of mitochondrial disorders has been accelerated by introducing Next-Generation Sequencing techniques in recent years, the treatment options are still very limited. For many patients only a supportive or symptomatic therapy is available at the moment. However, decades of basic and preclinical research have uncovered potential target points and numerous compounds or interventions are now subjects of clinical trials. In this review, we focus on current and emerging therapeutic approaches towards the treatment of mitochondrial disorders. We focus on small compounds, metabolic interference, such as endurance training or ketogenic diet and also on genomic approaches.

Laboratory of Bioenergetics Institute of Physiology Czech Acad Sci Prague Czech Republic

See more in PubMed

ABDELMALAK M, LEW A, RAMEZANI R, SHROADS AL, COATS BS, LANGAEE T, SHANKAR MN, NEIBERGER RE, SUBRAMONY SH, STACPOOLE PW. Long-term safety of dichloroacetate in congenital lactic acidosis. Mol Genet Metab. 2013;109:139–143. doi: 10.1016/j.ymgme.2013.03.019. PubMed DOI PMC

ABRAHAMYAN L, FELDMAN BM, TOMLINSON G, FAUGHNAN ME, JOHNSON SR, DIAMOND IR, GUPTA S. Alternative designs for clinical trials in rare diseases. Am J Med Genet C Semin Med Genet. 2016;172:313–331. doi: 10.1002/ajmg.c.31533. PubMed DOI

ACOSTA MJ, VAZQUEZ FONSECA L, DESBATS MA, CERQUA C, ZORDAN R, TREVISSON E, SALVIATI L. Coenzyme Q biosynthesis in health and disease. Biochim Biophys Acta. 2016;1857:1079–1085. doi: 10.1016/j.bbabio.2016.03.036. PubMed DOI

AHOLA-ERKKILÄ S, CARROLL CJ, PELTOLA-MJÖSUND K, TULKKI V, MATTILA I, SEPPÄNEN-LAAKSO T, ORESIC M, TYYNISMAA H, SUOMALAINEN A. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet. 2010;19:1974–1984. doi: 10.1093/hmg/ddq076. PubMed DOI

AHOLA S, AURANEN M, ISOHANNI P, NIEMISALO S, URHO N, BUZKOVA J, VELAGAPUDI V, LUNDBOM N, HAKKARAINEN A, MUURINEN T, PIIRILÄ P, PIETILÄINEN KH, SUOMALAINEN A. Modified Atkins diet induces subacute selective ragged-red-fiber lysis in mitochondrial myopathy patients. EMBO Mol Med. 2016;8:1234–1247. doi: 10.15252/emmm.201606592. PubMed DOI PMC

ALEXEYEV MF, VENEDIKTOVA N, PASTUKH V, SHOKOLENKO I, BONILLA G, WILSON GL. Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MILS syndromes. Gene Ther. 2008;15:516–523. doi: 10.1038/gt.2008.11. PubMed DOI PMC

AST T, MEISEL JD, PATRA S, WANG H, GRANGE RMH, KIM SH, CALVO SE, OREFICE LL, NAGASHIMA F, ICHINOSE F, ZAPOL WM, RUVKUN G, BARONDEAU DP, MOOTHA VK. Hypoxia rescues frataxin loss by restoring iron sulfur cluster biogenesis. Cell. 2019;177:1507–1521 e1516. doi: 10.1016/j.cell.2019.03.045. PubMed DOI PMC

AWAD AM, BRADLEY MC, FERNÁNDEZ-DEL-RÍO L, NAG A, TSUI HS, CLARKE CF. Coenzyme Q(10) deficiencies: pathways in yeast and humans. Essays Biochem. 2018;62:361–376. doi: 10.1042/EBC20170106. PubMed DOI PMC

BACMAN SR, KAUPPILA JHK, PEREIRA CV, NISSANKA N, MIRANDA M, PINTO M, WILLIAMS SL, LARSSON NG, STEWART JB, MORAES CT. MitoTALEN reduces mutant mtDNA load and restores tRNA(Ala) levels in a mouse model of heteroplasmic mtDNA mutation. Nat Med. 2018;24:1696–1700. doi: 10.1038/s41591-018-0166-8. PubMed DOI PMC

BACMAN SR, WILLIAMS SL, HERNANDEZ D, MORAES CT. Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a ‘differential multiple cleavage-site’ model. Gene Ther. 2007;14:1309–1318. doi: 10.1038/sj.gt.3302981. PubMed DOI PMC

BACMAN SR, WILLIAMS SL, PINTO M, PERALTA S, MORAES CT. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med. 2013;19:1111–1113. doi: 10.1038/nm.3261. PubMed DOI PMC

BAKER M. Gene-editing nucleases. Nat Methods. 2012;9:23–26. doi: 10.1038/nmeth.1807. PubMed DOI

BALASUBRAMANIAM S, CHRISTODOULOU J, RAHMAN S. Disorders of riboflavin metabolism. J Inherit Metab Dis. 2019;42:608–619. doi: 10.1002/jimd.12058. PubMed DOI

BARSHOP BA, NAVIAUX RK, MCGOWAN KA, LEVINE F, NYHAN WL, LOUPIS-GELLER A, HAAS RH. Chronic treatment of mitochondrial disease patients with dichloroacetate. Mol Genet Metab. 2004;83:138–149. doi: 10.1016/j.ymgme.2004.06.009. PubMed DOI

BATES MG, NEWMAN JH, JAKOVLJEVIC DG, HOLLINGSWORTH KG, ALSTON CL, ZALEWSKI P, KLAWE JJ, BLAMIRE AM, MacGOWAN GA, KEAVNEY BD, BOURKE JP, SCHAEFER A, McFARLAND R, NEWTON JL, TURNBULL DM, TAYLOR RW, TRENELL MI, GORMAN GS. Defining cardiac adaptations and safety of endurance training in patients with m.3243A>G-related mitochondrial disease. Int J Cardiol. 2013;168:3599–3608. doi: 10.1016/j.ijcard.2013.05.062. PubMed DOI PMC

BAYONA-BAFALUY MP, BLITS B, BATTERSBY BJ, SHOUBRIDGE EA, MORAES CT. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease. Proc Natl Acad Sci U S A. 2005;102:14392–14397. doi: 10.1073/pnas.0502896102. PubMed DOI PMC

BELENKY P, BOGAN KL, BRENNER C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007;32:12–19. doi: 10.1016/j.tibs.2006.11.006. PubMed DOI

BÉNIT P, GONCALVES S, DASSA EP, BRIÈRE JJ, RUSTIN P. The variability of the harlequin mouse phenotype resembles that of human mitochondrial-complex I-deficiency syndromes. PLoS One. 2008;3:e3208. doi: 10.1371/journal.pone.0003208. PubMed DOI PMC

BIAN WP, CHEN YL, LUO JJ, WANG C, XIE SL, PEI DS. Knock-in strategy for editing human and zebrafish mitochondrial DNA using Mito-CRISPR/Cas9 system. ACS Synth Biol. 2019;8:621–632. doi: 10.1021/acssynbio.8b00411. PubMed DOI

BILLINGTON RA, BRUZZONE S, De FLORA A, GENAZZANI AA, KOCH-NOLTE F, ZIEGLER M, ZOCCHI E. Emerging functions of extracellular pyridine nucleotides. Mol Med. 2006;12:324–327. doi: 10.2119/2006-00075.Billington. PubMed DOI PMC

BLÁZQUEZ-BERMEJO C, MOLINA-GRANADA D, VILA-JULIÀ F, JIMÉNEZ-HEIS D, ZHOU X, TORRES-TORRONTERAS J, KARLSSON A, MARTÍ R, CÁMARA Y. Age-related metabolic changes limit efficacy of deoxynucleoside-based therapy in thymidine kinase 2-deficient mice. EBioMedicine. 2019;46:342–355. doi: 10.1016/j.ebiom.2019.07.042. PubMed DOI PMC

BONNEFONT JP, BASTIN J, LAFORÊT P, AUBEY F, MOGENET A, ROMANO S, RICQUIER D, GOBIN-LIMBALLE S, VASSAULT A, BEHIN A, EYMARD B, BRESSON JL, DJOUADI F. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther. 2010;88:101–108. doi: 10.1038/clpt.2010.55. PubMed DOI

BOUQUET C, VIGNAL CLERMONT C, GALY A, FITOUSSI S, BLOUIN L, MUNK MR, VALERO S, MEUNIER S, KATZ B, SAHEL JA, THOMASSON N. Immune response and intraocular inflammation in patients with leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1/2 clinical trial. Jama Ophthalmol. 2019;137:399–406. doi: 10.1001/jamaophthalmol.2018.6902. PubMed DOI PMC

BUYSE G, MERTENS L, Di SALVO G, MATTHIJS I, WEIDEMANN F, EYSKENS B, GOOSSENS W, GOEMANS N, SUTHERLAND GR, Van HOVE JL. Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology. 2003;60:1679–1681. doi: 10.1212/01.WNL.0000068549.52812.0F. PubMed DOI

CAGLAYAN AO, GUMUS H, SANDFORD E, KUBISIAK TL, MA Q, OZEL AB, PER H, LI JZ, SHAKKOTTAI VG, BURMEISTER M. COQ4 mutation leads to childhood-onset ataxia improved by CoQ10 administration. Cerebellum. 2019;18:665–669. doi: 10.1007/s12311-019-01011-x. PubMed DOI PMC

CEDIKOVA M, PITULE P, KRIPNEROVA M, MARKOVA M, KUNCOVA J. Multiple roles of mitochondria in aging processes. Physiol Res. 2016;65:S519–S531. doi: 10.33549/physiolres.933538. PubMed DOI

CERUTTI R, PIRINEN E, LAMPERTI C, MARCHET S, SAUVE AA, LI W, LEONI V, SCHON EA, DANTZER F, AUWERX J, VISCOMI C, ZEVIANI M. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab. 2014;19:1042–1049. doi: 10.1016/j.cmet.2014.04.001. PubMed DOI PMC

CIVILETTO G, DOGAN SA, CERUTTI R, FAGIOLARI G, MOGGIO M, LAMPERTI C, BENINCÁ C, VISCOMI C, ZEVIANI M. Rapamycin rescues mitochondrial myopathy via coordinated activation of autophagy and lysosomal biogenesis. EMBO Mol Med. 2018;10 doi: 10.15252/emmm.201708799. PubMed DOI PMC

CLARK-MATOTT J, SALEEM A, DAI Y, SHURUBOR Y, MA X, SAFDAR A, BEAL MF, TARNOPOLSKY M, SIMON DK. Metabolomic analysis of exercise effects in the POLG mitochondrial DNA mutator mouse brain. Neurobiol Aging. 2015;36:2972–2983. doi: 10.1016/j.neurobiolaging.2015.07.020. PubMed DOI PMC

COHEN IG, ADASHI EY, GERKE S, PALACIOS-GONZÁLEZ C, RAVITSKY V. The regulation of mitochondrial replacement techniques around the world. Annu Rev Genomics Hum Genet. 2020 doi: 10.1146/annurev-genom-111119-101815. PubMed DOI

D’ANGELO R, RINALDI R, PIRONI L, DOTTI MT, PINNA AD, BOSCHETTI E, CAPRISTO M, MOHAMED S, CONTIN M, CAPORALI L, CARELLI V, De GIORGIO R. Liver transplant reverses biochemical imbalance in mitochondrial neurogastrointestinal encephalomyopathy. Mitochondrion. 2017;34:101–102. doi: 10.1016/j.mito.2017.02.006. PubMed DOI

DAI Y, ZHENG K, CLARK J, SWERDLOW RH, PULST SM, SUTTON JP, SHINOBU LA, SIMON DK. Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. Hum Mol Genet. 2014;23:637–647. doi: 10.1093/hmg/ddt450. PubMed DOI PMC

De GIORGIO R, PIRONI L, RINALDI R, BOSCHETTI E, CAPORALI L, CAPRISTO M, CASALI C, CENACCHI G, CONTIN M, D’ANGELO R, D’ERRICO A, GRAMEGNA LL, LODI R, MARESCA A, MOHAMED S, MORELLI MC, PAPA V, TONON C, TUGNOLI V, CARELLI V, D’ALESSANDRO R, PINNA AD. Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Ann Neurol. 2016;80:448–455. doi: 10.1002/ana.24724. PubMed DOI

De HAAS R, DAS D, GARANTO A, RENKEMA HG, GREUPINK R, Van DEN BROEK P, PERTIJS J, COLLIN RWJ, WILLEMS P, BEYRATH J, HEERSCHAP A, RUSSEL FG, SMEITINK JA. Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease. Sci Rep. 2017;7:11733. doi: 10.1038/s41598-017-09417-5. PubMed DOI PMC

Di PROSPERO NA, BAKER A, JEFFRIES N, FISCHBECK KH. Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6:878–886. doi: 10.1016/S1474-4422(07)70220-X. PubMed DOI

DILLON LM, HIDA A, GARCIA S, PROLLA TA, MORAES CT. Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse. PLoS One. 2012;7:e44335. doi: 10.1371/journal.pone.0044335. PubMed DOI PMC

DIONISI-VICI C, DIODATO D, TORRE G, PICCA S, PARIANTE R, GIUSEPPE PICARDO S, DI MEO I, RIZZO C, TIRANTI V, ZEVIANI M, DE VILLE DE GOYET J. Liver transplant in ethylmalonic encephalopathy: a new treatment for an otherwise fatal disease. Brain. 2016;139:1045–1051. doi: 10.1093/brain/aww013. PubMed DOI

DISTELMAIER F, HAACK TB, WORTMANN SB, MAYR JA, PROKISCH H. Treatable mitochondrial diseases: cofactor metabolism and beyond. Brain. 2017;140:e11. doi: 10.1093/brain/aww303. PubMed DOI

DOMÍNGUEZ-GONZÁLEZ C, MADRUGA-GARRIDO M, MAVILLARD F, GARONE C, AGUIRRE-RODRÍGUEZ FJ, DONATI MA, KLEINSTEUBER K, MARTÍ I, MARTÍN-HERNÁNDEZ E, MOREALEJO-AYCINENA JP, MUNELL F, NASCIMENTO A, KALKO SG, SARDINA MD, ÁLVAREZ Del VAYO C, SERRANO O, LONG Y, TU Y, LEVIN B, THOMPSON JLP, ENGELSTAD K, UDDIN J, TORRES-TORRONTERAS J, JIMENEZ-MALLEBRERA C, MARTÍ R, PARADAS C, HIRANO M. Deoxynucleoside therapy for thymidine kinase 2-deficient myopathy. Ann Neurol. 2019;86:293–303. doi: 10.1002/ana.25506. PubMed DOI PMC

DOUIEV L, SHEFFER R, HORVATH G, SAADA A. Bezafibrate improves mitochondrial fission and function in DNM1L-deficient patient cells. Cells. 2020;9 doi: 10.3390/cells9020301. PubMed DOI PMC

EHINGER JK, PIEL S, FORD R, KARLSSON M, SJÖVALL F, FROSTNER E, MOROTA S, TAYLOR RW, TURNBULL DM, CORNELL C, MOSS SJ, METZSCH C, HANSSON MJ, FLIRI H, ELMÉR E. Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency. Nat Commun. 2016;7:12317. doi: 10.1038/ncomms12317. PubMed DOI PMC

EL-HATTAB AW, ZARANTE AM, ALMANNAI M, SCAGLIA F. Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab. 2017;122:1–9. doi: 10.1016/j.ymgme.2017.09.009. PubMed DOI PMC

EMA: European Medicines Agency. CHMP ASSESSMENT REPORT FOR Sovrima. 2008.

EMPERADOR S, LÓPEZ-GALLARDO E, HERNÁNDEZ-AINSA C, HABBANE M, MONTOYA J, BAYONA-BAFALUY MP, RUIZ-PESINI E. Ketogenic treatment reduces the percentage of a LHON heteroplasmic mutation and increases mtDNA amount of a LHON homoplasmic mutation. Orphanet J Rare Dis. 2019;14:150. doi: 10.1186/s13023-019-1128-z. PubMed DOI PMC

MARTÍ R, HIRANO M. ENMC. Recommendations for treatment of mitochondrial DNA maintenance disorders (232nd ENMC International Workshop); 2017. PubMed

ENNS GM. Treatment of mitochondrial disorders: antioxidants and beyond. J Child Neurol. 2014;29:1235–1240. doi: 10.1177/0883073814538509. PubMed DOI

FERRARI M, JAIN IH, GOLDBERGER O, REZOAGLI E, THOONEN R, CHENG KH, SOSNOVIK DE, SCHERRER-CROSBIE M, MOOTHA VK, ZAPOL WM. Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome. Proc Natl Acad Sci U S A. 2017;114:E4241–e4250. doi: 10.1073/pnas.1621511114. PubMed DOI PMC

FERRIERO R, IANNUZZI C, MANCO G, BRUNETTI-PIERRI N. Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate. J Inherit Metab Dis. 2015;38:895–904. doi: 10.1007/s10545-014-9808-2. PubMed DOI PMC

FEUER WJ, SCHIFFMAN JC, DAVIS JL, PORCIATTI V, GONZALEZ P, KOILKONDA RD, YUAN H, LALWANI A, LAM BL, GUY J. Gene therapy for leber hereditary optic neuropathy: initial results. Ophthalmology. 2016;123:558–570. doi: 10.1016/j.ophtha.2015.10.025. PubMed DOI PMC

FIUZA-LUCES C, DÍEZ-BERMEJO J, FERNÁNDEZ DELATM, RODRÍGUEZ-ROMO G, SANZ-AYÁN P, DELMIRO A, MUNGUÍA-IZQUIERDO D, RODRÍGUEZ-GÓMEZ I, ARA I, DOMÍNGUEZ-GONZÁLEZ C, ARENAS J, MARTÍN MA, LUCIA A, MORÁN M. Health benefits of an innovative exercise program for mitochondrial disorders. Med Sci Sports Exerc. 2018;50:1142–1151. doi: 10.1249/MSS.0000000000001546. PubMed DOI

FIUZA-LUCES C, VALENZUELA PL, LAINE-MENÉNDEZ S, FERNÁNDEZ-DE LA TORRE M, BERMEJO-GÓMEZ V, RUFIÁN-VÁZQUEZ L, ARENAS J, MARTÍN MA, LUCIA A, MORÁN M. Physical exercise and mitochondrial disease: insights from a mouse model. Front Neurol. 2019;10:790. doi: 10.3389/fneur.2019.00790. PubMed DOI PMC

FREISINGER P, HORVATH R, MacMILLAN C, PETERS J, JAKSCH M. Reversion of hypertrophic cardiomyopathy in a patient with deficiency of the mitochondrial copper binding protein Sco2: is there a potential effect of copper? J Inherit Metab Dis. 2004;27:67–79. doi: 10.1023/B:BOLI.0000016614.47380.2f. PubMed DOI

GAMMAGE PA, MORAES CT, MINCZUK M. Mitochondrial genome engineering: the revolution may not be CRISPR-Ized. Trends Genet. 2018a;34:101–110. doi: 10.1016/j.tig.2017.11.001. PubMed DOI PMC

GAMMAGE PA, RORBACH J, VINCENT AI, REBAR EJ, MINCZUK M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol Med. 2014;6:458–466. doi: 10.1002/emmm.201303672. PubMed DOI PMC

GAMMAGE PA, VISCOMI C, SIMARD ML, COSTA ASH, GAUDE E, POWELL CA, van HAUTE L, McCANN BJ, REBELO-GUIOMAR P, CERUTTI R, ZHANG L, REBAR EJ, ZEVIANI M, FREZZA C, STEWART JB, MINCZUK M. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo. Nat Med. 2018b;24:1691–1695. doi: 10.1038/s41591-018-0165-9. PubMed DOI PMC

GARONE C, GARCIA-DIAZ B, EMMANUELE V, LOPEZ LC, TADESSE S, AKMAN HO, TANJI K, QUINZII CM, HIRANO M. Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Mol Med. 2014;6:1016–1027. doi: 10.15252/emmm.201404092. PubMed DOI PMC

GARONE C, VISCOMI C. Towards a therapy for mitochondrial disease: an update. Biochem Soc Trans. 2018;46:1247–1261. doi: 10.1042/BST20180134. PubMed DOI PMC

GENSIGHT B. GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history; Paris, France. 2019.

GLOVER EI, MARTIN J, MAHER A, THORNHILL RE, MORAN GR, TARNOPOLSKY MA. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve. 2010;42:739–748. doi: 10.1002/mus.21758. PubMed DOI

GÓMEZ-TATAY L, HERNÁNDEZ-ANDREU JM, AZNAR J. Mitochondrial Modification Techniques and Ethical Issues. J Clin Med. 2017;6 doi: 10.3390/jcm6030025. PubMed DOI PMC

GORMAN GS, CHINNERY PF, DIMAURO S, HIRANO M, KOGA Y, McFARLAND R, SUOMALAINEN A, THORBURN DR, ZEVIANI M, TURNBULL DM. Mitochondrial diseases. Nat Rev Dis Primers. 2016;2:16080. doi: 10.1038/nrdp.2016.80. PubMed DOI

GRADY JP, CAMPBELL G, RATNAIKE T, BLAKELY EL, FALKOUS G, NESBITT V, SCHAEFER AM, McNALLY RJ, GORMAN GS, TAYLOR RW, TURNBULL DM, McFARLAND R. Disease progression in patients with single, large-scale mitochondrial DNA deletions. Brain. 2014;137:323–334. doi: 10.1093/brain/awt321. PubMed DOI PMC

GRAY LR, TOMPKINS SC, TAYLOR EB. Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci. 2014;71:2577–2604. doi: 10.1007/s00018-013-1539-2. PubMed DOI PMC

GUSIC M, SCHOTTMANN G, FEICHTINGER RG, DU C, SCHOLZ C, WAGNER M, MAYR JA, LEE CY, YÉPEZ VA, LORENZ N, MORALES-GONZALEZ S, PANNEMAN DM, RÖTIG A, RODENBURG RJT, WORTMANN SB, PROKISCH H, SCHUELKE M. Bi-Allelic UQCRFS1 variants are associated with mitochondrial complex III deficiency, cardiomyopathy, and alopecia totalis. Am J Hum Genet. 2020;106:102–111. doi: 10.1016/j.ajhg.2019.12.005. PubMed DOI PMC

HAACK TB, DANHAUSER K, HABERBERGER B, HOSER J, STRECKER V, BOEHM D, UZIEL G, LAMANTEA E, INVERNIZZI F, POULTON J, ROLINSKI B, IUSO A, BISKUP S, SCHMIDT T, MEWES HW, WITTIG I, MEITINGER T, ZEVIANI M, PROKISCH H. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet. 2010;42:1131–1134. doi: 10.1038/ng.706. PubMed DOI

HAACK TB, KLEE D, STROM TM, MAYATEPEK E, MEITINGER T, PROKISCH H, DISTELMAIER F. Infantile Leigh-like syndrome caused by SLC19A3 mutations is a treatable disease. Brain. 2014;137:e295. doi: 10.1093/brain/awu128. PubMed DOI

HADRAVA VANOVA K, KRAUS M, NEUZIL J, ROHLENA J. Mitochondrial complex II and reactive oxygen species in disease and therapy. Redox Rep. 2020;25:26–32. doi: 10.1080/13510002.2020.1752002. PubMed DOI PMC

HALLIWELL B, GUTTERIDGE JMC. Free radicals in biology and medicine. Oxford University Press; 2015. DOI

HALTER JP, MICHAEL W, SCHÜPBACH M, MANDEL H, CASALI C, ORCHARD K, COLLIN M, VALCARCEL D, ROVELLI A, FILOSTO M, DOTTI MT, MAROTTA G, PINTOS G, BARBA P, ACCARINO A, FERRA C, ILLA I, BEGUIN Y, BAKKER JA, BOELENS JJ, DE COO IF, FAY K, SUE CM, NACHBAUR D, ZOLLER H, SOBREIRA C, PINTO SIMOES B, HAMMANS SR, SAVAGE D, MARTÍ R, CHINNERY PF, ELHASID R, GRATWOHL A, HIRANO M. Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain. 2015;138:2847–2858. doi: 10.1093/brain/awv226. PubMed DOI PMC

HANDSCHIN C, SPIEGELMAN BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006;27:728–735. doi: 10.1210/er.2006-0037. PubMed DOI

HARGREAVES IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol. 2014;49:105–111. doi: 10.1016/j.biocel.2014.01.020. PubMed DOI

HARTMAN AL, VINING EP. Clinical aspects of the ketogenic diet. Epilepsia. 2007;48:31–42. doi: 10.1111/j.1528-1167.2007.00914.x. PubMed DOI

HASAN-OLIVE MM, LAURITZEN KH, ALI M, RASMUSSEN LJ, STORM-MATHISEN J, BERGERSEN LH. A ketogenic diet improves mitochondrial biogenesis and bioenergetics via the PGC1α-SIRT3-UCP2 axis. Neurochem Res. 2019;44:22–37. doi: 10.1007/s11064-018-2588-6. PubMed DOI

HASHIMOTO M, BACMAN SR, PERALTA S, FALK MJ, CHOMYN A, CHAN DC, WILLIAMS SL, MORAES CT. MitoTALEN: A general approach to reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases. Mol Ther. 2015;23:1592–1599. doi: 10.1038/mt.2015.126. PubMed DOI PMC

HEJZLAROVÁ K, KAPLANOVÁ V, NŮSKOVÁ H, KOVÁŘOVÁ N, JEŠINA P, DRAHOTA Z, MRÁČEK T, SENECA S, HOUŠTĚK J. Alteration of structure and function of ATP synthase and cytochrome c oxidase by lack of Fo-a and Cox3 subunits caused by mitochondrial DNA 9205delTA mutation. Biochem J. 2015;466:601–611. doi: 10.1042/BJ20141462. PubMed DOI

HENZE K, MARTIN W. Evolutionary biology: essence of mitochondria. Nature. 2003;426:127–128. doi: 10.1038/426127a. PubMed DOI

HIRANO M, EMMANUELE V, QUINZII CM. Emerging therapies for mitochondrial diseases. Essays Biochem. 2018;62:467–481. doi: 10.1042/EBC20170114. PubMed DOI PMC

HOFER A, NOE N, TISCHNER C, KLADT N, LELLEK V, SCHAUß A, WENZ T. Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo. Hum Mol Genet. 2014;23:2400–2415. doi: 10.1093/hmg/ddt631. PubMed DOI

HOLZEROVA E, DANHAUSER K, HAACK TB, KREMER LS, MELCHER M, INGOLD I, KOBAYASHI S, TERRILE C, WOLF P, SCHAPER J, MAYATEPEK E, BAERTLING F, FRIEDMANN ANGELI JP, CONRAD M, STROM TM, MEITINGER T, PROKISCH H, DISTELMAIER F. Human thioredoxin 2 deficiency impairs mitochondrial redox homeostasis and causes early-onset neurodegeneration. Brain. 2016;139:346–354. doi: 10.1093/brain/awv350. PubMed DOI

HOLZEROVÁ E, PROKISCH H. Mitochondria: Much ado about nothing? How dangerous is reactive oxygen species production? Int J Biochem Cell Biol. 2015;63:16–20. doi: 10.1016/j.biocel.2015.01.021. PubMed DOI PMC

HORVATH R. Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ 10) J Inherit Metab Dis. 2012;35:679–687. doi: 10.1007/s10545-011-9434-1. PubMed DOI

HSU PD, LANDER ES, ZHANG F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262–1278. doi: 10.1016/j.cell.2014.05.010. PubMed DOI PMC

HUSSAIN S-RA, YALVAC ME, KHOO B, ECKARDT S, McLAUGHLIN KJ. Adapting CRISPR/Cas9 system for targeting mitochondrial genome. bioRxiv. 2020 doi: 10.1101/2020.02.11.944819. PubMed DOI PMC

HYSLOP LA, BLAKELEY P, CRAVEN L, RICHARDSON J, FOGARTY NM, FRAGOULI E, LAMB M, WAMAITHA SE, PRATHALINGAM N, ZHANG Q, O’KEEFE H, TAKEDA Y, ARIZZI L, ALFARAWATI S, TUPPEN HA, IRVING L, KALLEAS D, CHOUDHARY M, WELLS D, MURDOCH AP, TURNBULL DM, NIAKAN KK, HERBERT M. Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature. 2016;534:383–386. doi: 10.1038/nature18303. PubMed DOI PMC

CHATFIELD KC, SPARAGNA GC, CHAU S, PHILLIPS EK, AMBARDEKAR AV, AFTAB M, MITCHELL MB, SUCHAROV CC, MIYAMOTO SD, STAUFFER BL. Elamipretide improves mitochondrial function in the failing human heart. JACC Basic Transl Sci. 2019;4:147–157. doi: 10.1016/j.jacbts.2018.12.005. PubMed DOI PMC

CHINNERY PF, TURNBULL DM. Epidemiology and treatment of mitochondrial disorders. Am J Med Genet. 2001;106:94–101. doi: 10.1002/ajmg.1426. PubMed DOI

CHO J, WON K, WU D, SOONG Y, LIU S, SZETO HH, HONG MK. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 2007;18:215–220. doi: 10.1097/01.mca.0000236285.71683.b6. PubMed DOI

ISHII T, HIBINO Y. Mitochondrial manipulation in fertility clinics: Regulation and responsibility. Reprod Biomed Soc Online. 2018;5:93–109. doi: 10.1016/j.rbms.2018.01.002. PubMed DOI PMC

JADIYA P, TOMAR D. Mitochondrial protein quality control mechanisms. Genes (Basel) 2020;11 doi: 10.3390/genes11050563. PubMed DOI PMC

JAIN IH, CALVO SE, MARKHARD AL, SKINNER OS, TO TL, AST T, MOOTHA VK. Genetic screen for cell fitness in high or low oxygen highlights mitochondrial and lipid metabolism. Cell. 2020;181:716–727 e711. doi: 10.1016/j.cell.2020.03.029. PubMed DOI PMC

JAIN IH, ZAZZERON L, GOLDBERGER O, MARUTANI E, WOJTKIEWICZ GR, AST T, WANG H, SCHLEIFER G, STEPANOVA A, BREPOELS K, SCHOONJANS L, CARMELIET P, GALKIN A, ICHINOSE F, ZAPOL WM, MOOTHA VK. Leigh syndrome mouse model can be rescued by interventions that normalize brain hyperoxia, but not HIF activation. Cell Metab. 2019;30:824–832 e823. doi: 10.1016/j.cmet.2019.07.006. PubMed DOI PMC

JAIN IH, ZAZZERON L, GOLI R, ALEXA K, SCHATZMAN-BONE S, DHILLON H, GOLDBERGER O, PENG J, SHALEM O, SANJANA NE, ZHANG F, GOESSLING W, ZAPOL WM, MOOTHA VK. Hypoxia as a therapy for mitochondrial disease. Science. 2016;352:54–61. doi: 10.1126/science.aad9642. PubMed DOI PMC

JANSSEN MCH, KOENE S, De LAAT P, HEMELAAR P, PICKKERS P, SPAANS E, BEUKEMA R, BEYRATH J, GROOTHUIS J, VERHAAK C, SMEITINK J. The KHENERGY Study: Safety and efficacy of KH176 in mitochondrial m.3243A>G spectrum disorders. Clin Pharmacol Ther. 2019;105:101–111. doi: 10.1002/cpt.1197. PubMed DOI PMC

JAUHARI P, SANKHYAN N, VYAS S, SINGHI P. Thiamine responsive pyruvate dehydrogenase complex deficiency: a potentially treatable cause of leigh’s disease. J Pediatr Neurosci. 2017;12:265–267. doi: 10.4103/jpn.JPN_191_16. PubMed DOI PMC

JEPPESEN TD, DUNØ M, SCHWARTZ M, KRAG T, RAFIQ J, WIBRAND F, VISSING J. Short- and long-term effects of endurance training in patients with mitochondrial myopathy. Eur J Neurol. 2009;16:1336–1339. doi: 10.1111/j.1468-1331.2009.02660.x. PubMed DOI

JEPPESEN TD, SCHWARTZ M, OLSEN DB, WIBRAND F, KRAG T, DUNØ M, HAUERSLEV S, VISSING J. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain. 2006;129:3402–3412. doi: 10.1093/brain/awl149. PubMed DOI

JO A, HAM S, LEE GH, LEE YI, KIM S, LEE YS, SHIN JH, LEE Y. Efficient Mitochondrial Genome Editing by CRISPR/Cas9. Biomed Res Int. 2015;2015:305716. doi: 10.1155/2015/305716. PubMed DOI PMC

JOHNSON SC, KAEBERLEIN M. Rapamycin in aging and disease: maximizing efficacy while minimizing side effects. Oncotarget. 2016;7:44876–44878. doi: 10.18632/oncotarget.10381. PubMed DOI PMC

JOHNSON SC, YANOS ME, KAYSER EB, QUINTANA A, SANGESLAND M, CASTANZA A, UHDE L, HUI J, WALL VZ, GAGNIDZE A, OH K, WASKO BM, RAMOS FJ, PALMITER RD, RABINOVITCH PS, MORGAN PG, SEDENSKY MM, KAEBERLEIN M. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science. 2013;342:1524–1528. doi: 10.1126/science.1244360. PubMed DOI PMC

KADOYA T, SAKAKIBARA A, KITAYAMA K, YAMADA Y, HIGUCHI S, KAWAKITA R, KAWASAKI Y, FUJINO M, MURAKAMI Y, SHIMURA M, MURAYAMA K, OHTAKE A, OKAZAKI Y, KOGA Y, YORIFUJI T. Successful treatment of infantile-onset ACAD9-related cardiomyopathy with a combination of sodium pyruvate, beta-blocker, and coenzyme Q10. J Pediatr Endocrinol Metab. 2019;32:1181–1185. doi: 10.1515/jpem-2019-0205. PubMed DOI

KAISER J, SCHRAMEK N, EBERHARDT S, PÜTTMER S, SCHUSTER M, BACHER A. Biosynthesis of vitamin B2. Eur J Biochem. 2002;269:5264–5270. doi: 10.1046/j.1432-1033.2002.03239.x. PubMed DOI

KARAA A, HAAS R, GOLDSTEIN A, VOCKLEY J, COHEN BH. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020 doi: 10.1002/jcsm.12559. PubMed DOI PMC

KARAA A, HAAS R, GOLDSTEIN A, VOCKLEY J, WEAVER WD, COHEN BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90:e1212–e1221. doi: 10.1212/WNL.0000000000005255. PubMed DOI PMC

KARAARSLAN C. Leber’s hereditary optic neuropathy as a promising disease for gene therapy development. Adv Ther. 2019;36:3299–3307. doi: 10.1007/s12325-019-01113-2. PubMed DOI PMC

KAUFMANN P, ENGELSTAD K, WEI Y, JHUNG S, SANO MC, SHUNGU DC, MILLAR WS, HONG X, GOOCH CL, MAO X, PASCUAL JM, HIRANO M, STACPOOLE PW, DIMAURO S, DE VIVO DC. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66:324–330. doi: 10.1212/01.wnl.0000196641.05913.27. PubMed DOI

KAUR A, SHARMA S. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases. Inflammopharmacology. 2017;25:293–312. doi: 10.1007/s10787-017-0336-1. PubMed DOI

KERR DS. Review of clinical trials for mitochondrial disorders: 1997–2012. Neurotherapeutics. 2013;10:307–319. doi: 10.1007/s13311-013-0176-7. PubMed DOI PMC

KHAN NA, AURANEN M, PAETAU I, PIRINEN E, EURO L, FORSSTRÖM S, PASILA L, VELAGAPUDI V, CARROLL CJ, AUWERX J, SUOMALAINEN A. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med. 2014;6:721–731. doi: 10.1002/emmm.201403943. PubMed DOI PMC

KHAN NA, NIKKANEN J, YATSUGA S, JACKSON C, WANG L, PRADHAN S, KIVELÄ R, PESSIA A, VELAGAPUDI V, SUOMALAINEN A. mTORC1 regulates mitochondrial integrated stress response and mitochondrial myopathy progression. Cell Metab. 2017;26:419–428.e415. doi: 10.1016/j.cmet.2017.07.007. PubMed DOI

KLOPSTOCK T, METZ G, YU-WAI-MAN P, BÜCHNER B, GALLENMÜLLER C, BAILIE M, NWALI N, GRIFFITHS PG, Von LIVONIUS B, REZNICEK L, ROULEAU J, COPPARD N, MEIER T, CHINNERY PF. Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy. Brain. 2013;136:e230. doi: 10.1093/brain/aws279. PubMed DOI PMC

KLOPSTOCK T, YU-WAI-MAN P, DIMITRIADIS K, ROULEAU J, HECK S, BAILIE M, ATAWAN A, CHATTOPADHYAY S, SCHUBERT M, GARIP A, KERNT M, PETRAKI D, RUMMEY C, LEINONEN M, METZ G, GRIFFITHS PG, MEIER T, CHINNERY PF. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain. 2011;134:2677–2686. doi: 10.1093/brain/awr170. PubMed DOI PMC

KOENE S, SMEITINK JAM. Mitochondrial medicine: a clinical guideline. Nijmegen; The Netherlands, Khondrion BV: 2011. DOI

KOENE S, SPAANS E, Van BORTEL L, Van LANCKER G, DELAFONTAINE B, BADILINI F, BEYRATH J, SMEITINK J. KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers. Orphanet J Rare Dis. 2017;12:163. doi: 10.1186/s13023-017-0715-0. PubMed DOI PMC

KREMER LS, DANHAUSER K, HEREBIAN D, PETKOVIC RAMADŽA D, PIEKUTOWSKA-ABRAMCZUK D, SEIBT A, MÜLLER-FELBER W, HAACK TB, PŁOSKI R, LOHMEIER K, SCHNEIDER D, KLEE D, ROKICKI D, MAYATEPEK E, STROM TM, MEITINGER T, KLOPSTOCK T, PRONICKA E, MAYR JA, BARIC I, DISTELMAIER F, PROKISCH H. NAXE Mutations Disrupt the Cellular NAD(P)HX Repair System and Cause a Lethal Neurometabolic Disorder of Early Childhood. Am J Hum Genet. 2016;99:894–902. doi: 10.1016/j.ajhg.2016.07.018. PubMed DOI PMC

KRIPPS K, NAKAYUENYONGSUK W, SHAYOTA BJ, BERQUIST W, GOMEZ-OSPINA N, ESQUIVEL CO, CONCEPCION W, SAMPSON JB, CRISTIN DJ, JACKSON WE, GILLILAND S, POMFRET EA, KUEHT ML, PETTIT RW, SHERIF YA, EMRICK LT, ELSEA SH, HIMES R, HIRANO M, Van HOVE JLK, SCAGLIA F, ENNS GM, LARSON AA. Successful liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) Mol Genet Metab. 2020;130:58–64. doi: 10.1016/j.ymgme.2020.03.001. PubMed DOI PMC

KWONG AK, CHIU AT, TSANG MH, LUN KS, RODENBURG RJT, SMEITINK J, CHUNG BH, FUNG CW. A fatal case of COQ7-associated primary coenzyme Q(10) deficiency. JIMD Rep. 2019;47:23–29. doi: 10.1002/jmd2.12032. PubMed DOI PMC

LAKE NJ, COMPTON AG, RAHMAN S, THORBURN DR. Leigh syndrome: One disorder, more than 75 monogenic causes. Ann Neurol. 2016;79:190–203. doi: 10.1002/ana.24551. PubMed DOI

LAMMING DW, YE L, SABATINI DM, BAUR JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 2013;123:980–989. doi: 10.1172/JCI64099. PubMed DOI PMC

LAURITZEN KH, HASAN-OLIVE MM, REGNELL CE, KLEPPA L, SCHEIBYE-KNUDSEN M, GJEDDE A, KLUNGLAND A, BOHR VA, STORM-MATHISEN J, BERGERSEN LH. A ketogenic diet accelerates neurodegeneration in mice with induced mitochondrial DNA toxicity in the forebrain. Neurobiol Aging. 2016;48:34–47. doi: 10.1016/j.neurobiolaging.2016.08.005. PubMed DOI PMC

LIENHART WD, GUDIPATI V, MACHEROUX P. The human flavoproteome. Arch Biochem Biophys. 2013;535:150–162. doi: 10.1016/j.abb.2013.02.015. PubMed DOI PMC

LIGHTOWLERS RN, TAYLOR RW, TURNBULL DM. Mutations causing mitochondrial disease: What is new and what challenges remain? Science. 2015;349:1494–1499. doi: 10.1126/science.aac7516. PubMed DOI

LOPEZ-GOMEZ C, LEVY RJ, SANCHEZ-QUINTERO MJ, JUANOLA-FALGARONA M, BARCA E, GARCIA-DIAZ B, TADESSE S, GARONE C, HIRANO M. Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency. Ann Neurol. 2017;81:641–652. doi: 10.1002/ana.24922. PubMed DOI PMC

LYSENG-WILLIAMSON KA. Idebenone: A review in leber’s hereditary optic neuropathy. Drugs. 2016;76:805–813. doi: 10.1007/s40265-016-0574-3. PubMed DOI

MADHOK J, LEONG J, COHN J. Anesthetic Considerations for Liver Transplantation in a Patient with Mitochondrial Neurogastrointestinal Encephalopathy Syndrome. Cureus. 2019;11:e5038. doi: 10.7759/cureus.5038. PubMed DOI PMC

MAGALHÃES PV, DEAN O, ANDREAZZA AC, BERK M, KAPCZINSKI F. Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev. 2016;2:Cd008919. doi: 10.1002/14651858.CD008919.pub2. PubMed DOI PMC

MAJAMAA K, RUSANEN H, REMES AM, PYHTINEN J, HASSINEN IE. Increase of blood NAD+ and attenuation of lactacidemia during nicotinamide treatment of a patient with the MELAS syndrome. Life Sci. 1996;58:691–699. doi: 10.1016/S0024-3205(96)80008-7. PubMed DOI

MANCUSO M, ANGELINI C, BERTINI E, CARELLI V, COMI GP, MINETTI C, MOGGIO M, MONGINI T, SERVIDEI S, TONIN P, TOSCANO A, UZIEL G, ZEVIANI M, SICILIANO G. Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases. Neuromuscul Disord. 2012;22(Suppl 3):S226–229. doi: 10.1016/j.nmd.2012.10.012. PubMed DOI PMC

MARCÉ-GRAU A, MARTÍ-SÁNCHEZ L, BAIDE-MAIRENA H, ORTIGOZA-ESCOBAR JD, PÉREZ-DUEÑAS B. Genetic defects of thiamine transport and metabolism: A review of clinical phenotypes, genetics, and functional studies. J Inherit Metab Dis. 2019;42:581–597. doi: 10.1002/jimd.12125. PubMed DOI

MARSHALL KG. Exploring antioxidants. West Indian Med J. 2014;63:119–120. PubMed PMC

MAYR JA, HAACK TB, FREISINGER P, KARALL D, MAKOWSKI C, KOCH J, FEICHTINGER RG, ZIMMERMANN FA, ROLINSKI B, AHTING U, MEITINGER T, PROKISCH H, SPERL W. Spectrum of combined respiratory chain defects. J Inherit Metab Dis. 2015;38:629–640. doi: 10.1007/s10545-015-9831-y. PubMed DOI PMC

McCANN BJ, COX A, GAMMAGE PA, STEWART JB, ZERNICKA-GOETZ M, MINCZUK M. Delivery of mtZFNs into Early Mouse Embryos. Methods Mol Biol. 2018;1867:215–228. doi: 10.1007/978-1-4939-8799-3_16. PubMed DOI

MILLER SA, DYMSZA HA. Utilization by the rat of 1,3-butanediol as a synthetic source of dietary energy. J Nutr. 1967;91:79–88. doi: 10.1093/jn/91.1.79. PubMed DOI

MOSTER M, SADUN A, KLOPSTOCK T, NEWMAN N, VIGNAL-CLERMONT C, CARELLI V, YU-WAI-MAN P, BIOUSSE V, SERGOTT R, KATZ B, DEBUSK A, BLOUIN L, CHEVALIER C, BURGUIERE P, TAIEL M, SAHEL JA. rAAV2/2-ND4 for the Treatment of Leber Hereditary Optic Neuropathy (LHON): Final Results from the RESCUE and REVERSE Phase III Clinical Trials and Experimental Data in Nonhuman Primates to Support a Bilateral Effect (2339) Neurology. 2020

MUNNICH A, RUSTIN P. Clinical spectrum and diagnosis of mitochondrial disorders. Am J Med Genet. 2001;106:4–17. doi: 10.1002/ajmg.1391. PubMed DOI

MURPHY JL, BLAKELY EL, SCHAEFER AM, HE L, WYRICK P, HALLER RG, TAYLOR RW, TURNBULL DM, TAIVASSALO T. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain. 2008;131:2832–2840. doi: 10.1093/brain/awn252. PubMed DOI

MURU K, REINSON K, KÜNNAPAS K, LILLEVÄLI H, NOCHI Z, MOSEGAARD S, PAJUSALU S, OLSEN RKJ, ÕUNAP K. FLAD1-associated multiple acyl-CoA dehydrogenase deficiency identified by newborn screening. Mol Genet Genomic Med. 2019;7:e915. doi: 10.1002/mgg3.915. PubMed DOI PMC

NUSKOVA H, MIKESOVA J, EFIMOVA I, PECINOVA A, PECINA P, DRAHOTA Z, HOUSTEK J, MRACEK T. Biochemical thresholds for pathological presentation of ATP synthase deficiencies. Biochem Biophys Res Commun. 2020;521:1036–1041. doi: 10.1016/j.bbrc.2019.11.033. PubMed DOI

O’DAY SJ, EGGERMONT AM, CHIARION-SILENI V, KEFFORD R, GROB JJ, MORTIER L, ROBERT C, SCHACHTER J, TESTORI A, MACKIEWICZ J, FRIEDLANDER P, GARBE C, UGUREL S, COLLICHIO F, GUO W, LUFKIN J, BAHCALL S, VUKOVIC V, HAUSCHILD A. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013;31:1211–1218. doi: 10.1200/JCO.2012.44.5585. PubMed DOI

OLSEN RK, OLPIN SE, ANDRESEN BS, MIEDZYBRODZKA ZH, POURFARZAM M, MERINERO B, FRERMAN FE, BERESFORD MW, DEAN JC, CORNELIUS N, ANDERSEN O, OLDFORS A, HOLME E, GREGERSEN N, TURNBULL DM, MORRIS AA. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain. 2007;130:2045–2054. doi: 10.1093/brain/awm135. PubMed DOI

OLSEN RKJ, KOŇAŘÍKOVÁ E, GIANCASPERO TA, MOSEGAARD S, BOCZONADI V, MATAKOVIĆ L, VEAUVILLE-MERLLIÉ A, TERRILE C, SCHWARZMAYR T, HAACK TB, AURANEN M, LEONE P, GALLUCCIO M, IMBARD A, GUTIERREZ-RIOS P, PALMFELDT J, GRAF E, VIANEY-SABAN C, OPPENHEIM M, SCHIFF M, PICHARD S, RIGAL O, PYLE A, CHINNERY PF, KONSTANTOPOULOU V, MÖSLINGER D, FEICHTINGER RG, TALIM B, TOPALOGLU H, COSKUN T, GUCER S, BOTTA A, PEGORARO E, MALENA A, VERGANI L, MAZZÀ D, ZOLLINO M, GHEZZI D, ACQUAVIVA C, TYNI T, BONEH A, MEITINGER T, STROM TM, GREGERSEN N, MAYR JA, HORVATH R, BARILE M, PROKISCH H. Riboflavin-responsive and -non-responsive mutations in FAD synthase cause multiple acyl-CoA dehydrogenase and combined respiratory-chain deficiency. Am J Hum Genet. 2016;98:1130–1145. doi: 10.1016/j.ajhg.2016.04.006. PubMed DOI PMC

ØRNGREEN MC, MADSEN KL, PREISLER N, ANDERSEN G, VISSING J, LAFORÊT P. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology. 2014;82:607–613. doi: 10.1212/WNL.0000000000000118. PubMed DOI PMC

ORTIGOZA-ESCOBAR JD, MOLERO-LUIS M, ARIAS A, MARTÍ-SÁNCHEZ L, RODRIGUEZ-POMBO P, ARTUCH R, PÉREZ-DUEÑAS B. Treatment of genetic defects of thiamine transport and metabolism. Expert Rev Neurothe. 2016;16:755–763. doi: 10.1080/14737175.2016.1187562. PubMed DOI

PAN J, WANG L, LU C, ZHU Y, MIN Z, DONG X, SHA H. Matching Mitochondrial DNA Haplotypes for Circumventing Tissue-Specific Segregation Bias. iScience. 2019;13:371–379. doi: 10.1016/j.isci.2019.03.002. PubMed DOI PMC

PARIKH S, SANETO R, FALK MJ, ANSELM I, COHEN BH, HAAS R MEDICINE SOCIETY TM. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol. 2009;11:414–430. doi: 10.1007/s11940-009-0046-0. PubMed DOI PMC

PATGIRI A, SKINNER OS, MIYAZAKI Y, SCHLEIFER G, MARUTANI E, SHAH H, SHARMA R, GOODMAN RP, TO TL, ROBERT BAO X, ICHINOSE F, ZAPOL WM, MOOTHA VK. An engineered enzyme that targets circulating lactate to alleviate intracellular NADH:NAD(+) imbalance. Nat Biotechnol. 2020;38:309–313. doi: 10.1038/s41587-019-0377-7. PubMed DOI PMC

PERALTA S, GARCIA S, YIN HY, ARGUELLO T, DIAZ F, MORAES CT. Sustained AMPK activation improves muscle function in a mitochondrial myopathy mouse model by promoting muscle fiber regeneration. Hum Mol Genet. 2016;25:3178–3191. doi: 10.1093/hmg/ddw167. PubMed DOI PMC

PEREIRA CV, BACMAN SR, ARGUELLO T, ZEKONYTE U, WILLIAMS SL, EDGELL DR, MORAES CT. mitoTev-TALE: a monomeric DNA editing enzyme to reduce mutant mitochondrial DNA levels. EMBO Mol Med. 2018;10 doi: 10.15252/emmm.201708084. PubMed DOI PMC

PEREIRA CV, MORAES CT. Current strategies towards therapeutic manipulation of mtDNA heteroplasmy. Front Biosci (Landmark Ed) 2017;22:991–1010. doi: 10.2741/4529. PubMed DOI PMC

PÉREZ-DUEÑAS B, SERRANO M, REBOLLO M, MUCHART J, GARGALLO E, DUPUITS C, ARTUCH R. Reversible lactic acidosis in a newborn with thiamine transporter-2 deficiency. Pediatrics. 2013;131:e1670–1675. doi: 10.1542/peds.2012-2988. PubMed DOI

PFEFFER G, MAJAMAA K, TURNBULL DM, THORBURN D, CHINNERY PF. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2012:Cd004426. doi: 10.1002/14651858.CD004426.pub3. PubMed DOI PMC

PHILLIPS IR, SHEPHARD EA. Primary Trimethylaminuria. In: ADAM MP, ARDINGER HH, PAGON RA, WALLACE SE, BEAN LJH, STEPHENS K, AMEMIYA A, editors. GeneReviews(®) University of Washington; Seattle (WA): 1993–2020. https://www.ncbi.nlm.nih.gov/books/NBK1103/

PIRINEN E, AURANEN M, KHAN NA, BRILHANTE V, URHO N, PESSIA A, HAKKARAINEN A, KUULA J, HEINONEN U, SCHMIDT MS, HAIMILAHTI K, PIIRILÄ P, LUNDBOM N, TASKINEN MR, BRENNER C, VELAGAPUDI V, PIETILÄINEN KH, SUOMALAINEN A. Niacin cures systemic NAD(+) deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metab. 2020 doi: 10.1016/j.cmet.2020.05.020. PubMed DOI

POMAHAČOVÁ R, ZAMBORYOVÁ J, SÝKORA J, PATEROVÁ P, FIKLÍK K, VOTAVA T, ČERNÁ Z, JEHLIČKA P, LÁD V, ŠUBRT I, DORT J, DORTOVÁ E. First 2 cases with thiamine-responsive megaloblastic anemia in the Czech Republic, a rare form of monogenic diabetes mellitus: a novel mutation in the thiamine transporter SLC19A2 gene-intron 1 mutation c.204+2T>G. Pediatr Diabetes. 2017;18:844–847. doi: 10.1111/pedi.12479. PubMed DOI

PORCELLI S, MARZORATI M, MORANDI L, GRASSI B. Home-based aerobic exercise training improves skeletal muscle oxidative metabolism in patients with metabolic myopathies. J Appl Physiol (1985) 2016;121:699–708. doi: 10.1152/japplphysiol.00885.2015. PubMed DOI

POTGIETER M, PRETORIUS E, PEPPER MS. Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutr Rev. 2013;71:180–188. doi: 10.1111/nure.12011. PubMed DOI

PURHONEN J, RAJENDRAN J, MÖRGELIN M, UUSI-RAUVA K, KATAYAMA S, KRJUTSKOV K, EINARSDOTTIR E, VELAGAPUDI V, KERE J, JAUHIAINEN M, FELLMAN V, KALLIJÄRVI J. Ketogenic diet attenuates hepatopathy in mouse model of respiratory chain complex III deficiency caused by a Bcs1l mutation. Sci Rep. 2017;7:957. doi: 10.1038/s41598-017-01109-4. PubMed DOI PMC

RAHMAN J, RAHMAN S. Mitochondrial medicine in the omics era. Lancet. 2018;391:2560–2574. doi: 10.1016/S0140-6736(18)30727-X. PubMed DOI

REARDON S. US panel greenlights creation of male ‘three-person’ embryos. Nature. 2016;530:142. doi: 10.1038/nature.2016.19290. PubMed DOI

REDDY PH, MANCZAK M, KANDIMALLA R. Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer’s disease. Hum Mol Genet. 2017;26:1597. doi: 10.1093/hmg/ddx129. PubMed DOI PMC

REPP BM, MASTANTUONO E, ALSTON CL, SCHIFF M, HAACK TB, RÖTIG A, ARDISSONE A, LOMBÈS A, CATARINO CB, DIODATO D, SCHOTTMANN G, POULTON J, BURLINA A, JONCKHEERE A, MUNNICH A, ROLINSKI B, GHEZZI D, ROKICKI D, WELLESLEY D, MARTINELLI D, WENHONG D, LAMANTEA E, OSTERGAARD E, PRONICKA E, PIERRE G, SMEETS HJM, WITTIG I, SCURR I, De COO IFM, MORONI I, SMET J, MAYR JA, DAI L, De MEIRLEIR L, SCHUELKE M, ZEVIANI M, MORSCHER RJ, McFARLAND R, SENECA S, KLOPSTOCK T, MEITINGER T, WIELAND T, STROM TM, HERBERG U, AHTING U, SPERL W, NASSOGNE MC, LING H, FANG F, FREISINGER P, Van COSTER R, STRECKER V, TAYLOR RW, HÄBERLE J, VOCKLEY J, PROKISCH H, WORTMANN S. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? Orphanet J Rare Dis. 2018;13:120. doi: 10.1186/s13023-018-0784-8. PubMed DOI PMC

RICH P. Chemiosmotic coupling: The cost of living. Nature. 2003;421:583. doi: 10.1038/421583a. PubMed DOI

ROBERTS MN, WALLACE MA, TOMILOV AA, ZHOU Z, MARCOTTE GR, TRAN D, PEREZ G, GUTIERREZ-CASADO E, KOIKE S, KNOTTS TA, IMAI DM, GRIFFEY SM, KIM K, HAGOPIAN K, MCMACKIN MZ, HAJ FG, BAAR K, CORTOPASSI GA, RAMSEY JJ, LOPEZ-DOMINGUEZ JA. A ketogenic diet extends longevity and healthspan in adult mice. Cell Metab. 2017;26:539–546.e535. doi: 10.1016/j.cmet.2017.08.005. PubMed DOI PMC

ROMERO-MOYA D, CASTAÑO J, SANTOS-OCAÑA C, NAVAS P, MENENDEZ P. Generation, genome edition and characterization of iPSC lines from a patient with coenzyme Q(10) deficiency harboring a heterozygous mutation in COQ4 gene. Stem Cell Res. 2017;24:144–147. doi: 10.1016/j.scr.2016.09.007. PubMed DOI

RUDOLPH G, DIMITRIADIS K, BÜCHNER B, HECK S, AL-TAMAMI J, SEIDENSTICKER F, RUMMEY C, LEINONEN M, MEIER T, KLOPSTOCK T. Effects of idebenone on color vision in patients with leber hereditary optic neuropathy. J Neuroophthalmol. 2013;33:30–36. doi: 10.1097/WNO.0b013e318272c643. PubMed DOI PMC

RUSKIN DN, ROSS JL, KAWAMURA M, Jr, RUIZ TL, GEIGER JD, MASINO SA. A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington’s disease. Physiol Behav. 2011;103:501–507. doi: 10.1016/j.physbeh.2011.04.001. PubMed DOI PMC

RUSSELL OM, GORMAN GS, LIGHTOWLERS RN, TURNBULL DM. Mitochondrial Diseases: Hope for the Future. Cell. 2020;181:168–188. doi: 10.1016/j.cell.2020.02.051. PubMed DOI

SAADA A. Insights into deoxyribonucleoside therapy for mitochondrial TK2 deficient mtDNA depletion. EBioMedicine. 2019;47:14–15. doi: 10.1016/j.ebiom.2019.08.005. PubMed DOI PMC

SAFDAR A, BOURGEOIS JM, OGBORN DI, LITTLE JP, HETTINGA BP, AKHTAR M, THOMPSON JE, MELOV S, MOCELLIN NJ, KUJOTH GC, PROLLA TA, TARNOPOLSKY MA. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc Natl Acad Sci U S A. 2011;108:4135–4140. doi: 10.1073/pnas.1019581108. PubMed DOI PMC

SAFDAR A, SALEEM A, TARNOPOLSKY MA. The potential of endurance exercise-derived exosomes to treat metabolic diseases. Nat Rev Endocrinol. 2016;12:504–517. doi: 10.1038/nrendo.2016.76. PubMed DOI

SAGE-SCHWAEDE A, ENGELSTAD K, SALAZAR R, CURCIO A, KHANDJI A, GARVIN JH, Jr, De VIVO DC. Exploring mTOR inhibition as treatment for mitochondrial disease. Ann Clin Transl Neurol. 2019;6:1877–1881. doi: 10.1002/acn3.50846. PubMed DOI PMC

SAMUELS DC, WONNAPINIJ P, CHINNERY PF. Preventing the transmission of pathogenic mitochondrial DNA mutations: Can we achieve long-term benefits from germ-line gene transfer? Hum Reprod. 2013;28:554–559. doi: 10.1093/humrep/des439. PubMed DOI PMC

SANTRA S, GILKERSON RW, DAVIDSON M, SCHON EA. Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol. 2004;56:662–669. doi: 10.1002/ana.20240. PubMed DOI

SATO Y, NAKAGAWA M, HIGUCHI I, OSAME M, NAITO E, OIZUMI K. Mitochondrial myopathy and familial thiamine deficiency. Muscle Nerve. 2000;23:1069–1075. doi: 10.1002/1097-4598(200007)23:7<1069::AID-MUS9>3.0.CO;2-0. PubMed DOI

SCIACCO M, BONILLA E, SCHON EA, DIMAURO S, MORAES CT. Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet. 1994;3:13–19. doi: 10.1093/hmg/3.1.13. PubMed DOI

SCHLEIFER G, MARUTANI E, FERRARI M, SHARMA R, SKINNER O, GOLDBERGER O, GRANGE RMH, PENEYRA K, MALHOTRA R, WEPLER M, ICHINOSE F, BLOCH DB, MOOTHA VK, ZAPOL WM. Impaired hypoxic pulmonary vasoconstriction in a mouse model of Leigh syndrome. Am J Physiol Lung Cell Mol Physiol. 2019;316:L391–L399. doi: 10.1152/ajplung.00419.2018. PubMed DOI PMC

SCHOLL-BÜRGI S, HÖLLER A, PICHLER K, MICHEL M, HABERLANDT E, KARALL D. Ketogenic diets in patients with inherited metabolic disorders. J Inherit Metab Dis. 2015;38:765–773. doi: 10.1007/s10545-015-9872-2. PubMed DOI

SIEGMUND SE, YANG H, SHARMA R, JAVORS M, SKINNER O, MOOTHA V, HIRANO M, SCHON EA. Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome. Hum Mol Genet. 2017;26:4588–4605. doi: 10.1093/hmg/ddx341. PubMed DOI PMC

SMEITINK JA. Mitochondrial disorders: clinical presentation and diagnostic dilemmas. J Inherit Metab Dis. 2003;26:199–207. doi: 10.1023/A:1024489218004. PubMed DOI

SOMA S, LATIMER AJ, CHUN H, VICARY AC, TIMBALIA SA, BOULET A, RAHN JJ, CHAN SSL, LEARY SC, KIM BE, GITLIN JD, GOHIL VM. Elesclomol restores mitochondrial function in genetic models of copper deficiency. Proc Natl Acad Sci U S A. 2018;115:8161–8166. doi: 10.1073/pnas.1806296115. PubMed DOI PMC

SRIVASTAVA S, DIAZ F, IOMMARINI L, AURE K, LOMBES A, MORAES CT. PGC-1alpha/beta induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Hum Mol Genet. 2009;18:1805–1812. doi: 10.1093/hmg/ddp093. PubMed DOI PMC

STACPOOLE PW, MARTYNIUK CJ, JAMES MO, CALCUTT NA. Dichloroacetate-induced peripheral neuropathy. Int Rev Neurobiol. 2019;145:211–238. doi: 10.1016/bs.irn.2019.05.003. PubMed DOI

STEELE H, GOMEZ-DURAN A, PYLE A, HOPTON S, NEWMAN J, STEFANETTI RJ, CHARMAN SJ, PARIKH JD, HE L, VISCOMI C, JAKOVLJEVIC DG, HOLLINGSWORTH KG, ROBINSON AJ, TAYLOR RW, BOTTOLO L, HORVATH R, CHINNERY PF. Metabolic effects of bezafibrate in mitochondrial disease. EMBO Mol Med. 2020;12:e11589. doi: 10.15252/emmm.201911589. PubMed DOI PMC

STENTON SL, PROKISCH H. Advancing genomic approaches to the molecular diagnosis of mitochondrial disease. Essays Biochem. 2018;62:399–408. doi: 10.1042/EBC20170110. PubMed DOI

STENTON SL, PROKISCH H. Genetics of mitochondrial diseases: Identifying mutations to help diagnosis. EBioMedicine. 2020;56:102784. doi: 10.1016/j.ebiom.2020.102784. PubMed DOI PMC

STEWART JB, CHINNERY PF. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet. 2015;16:530–542. doi: 10.1038/nrg3966. PubMed DOI

SUOMALAINEN A, BATTERSBY BJ. Mitochondrial diseases: the contribution of organelle stress responses to pathology. Nat Rev Mol Cell Biol. 2018;19:77–92. doi: 10.1038/nrm.2017.66. PubMed DOI

TAIVASSALO T, GARDNER JL, TAYLOR RW, SCHAEFER AM, NEWMAN J, BARRON MJ, HALLER RG, TURNBULL DM. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain. 2006;129:3391–3401. doi: 10.1093/brain/awl282. PubMed DOI

TAIVASSALO T, JENSEN TD, KENNAWAY N, DIMAURO S, VISSING J, HALLER RG. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain. 2003;126:413–423. doi: 10.1093/brain/awg028. PubMed DOI

TAM A, ALDHAHERI NS, MYSORE K, TESSIER ME, GOSS J, FERNANDEZ LA, D’ALESSANDRO AM, SCHWOERER JS, RICE GM, ELSEA SH, SCAGLIA F. Improved clinical outcome following liver transplant in patients with ethylmalonic encephalopathy. Am J Med Genet A. 2019;179:1015–1019. doi: 10.1002/ajmg.a.61104. PubMed DOI PMC

TAN EY, BOELENS JJ, JONES SA, WYNN RF. Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism. Front Pediatr. 2019;7:433. doi: 10.3389/fped.2019.00433. PubMed DOI PMC

TANAKA M, BORGELD HJ, ZHANG J, MURAMATSU S, GONG JS, YONEDA M, MARUYAMA W, NAOI M, IBI T, SAHASHI K, SHAMOTO M, FUKU N, KURATA M, YAMADA Y, NISHIZAWA K, AKAO Y, OHISHI N, MIYABAYASHI S, UMEMOTO H, MURAMATSU T, FURUKAWA K, KIKUCHI A, NAKANO I, OZAWA K, YAGI K. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J Biomed Sci. 2002;9:534–541. doi: 10.1007/BF02254980. PubMed DOI

TAYLOR RW, TURNBULL DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet. 2005;6:389–402. doi: 10.1038/nrg1606. PubMed DOI PMC

THORBURN DR. Mitochondrial disorders: prevalence, myths and advances. J Inherit Metab Dis. 2004;27:349–362. doi: 10.1023/B:BOLI.0000031098.41409.55. PubMed DOI

TIRANTI V, VISCOMI C, HILDEBRANDT T, DI MEO I, MINERI R, TIVERON C, LEVITT MD, PRELLE A, FAGIOLARI G, RIMOLDI M, ZEVIANI M. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat Med. 2009;15:200–205. doi: 10.1038/nm.1907. PubMed DOI

TONON C, LODI R. Idebenone in Friedreich’s ataxia. Expert Opin Pharmacother. 2008;9:2327–2337. doi: 10.1517/14656566.9.13.2327. PubMed DOI

TRINH J, IMHOFF S, DULOVIC-MAHLOW M, KANDASWAMY KK, TADIC V, SCHÄFER J, DOBRICIC V, NOLTE A, WERBER M, ROLFS A, MÜNCHAU A, KLEIN C, LOHMANN K, BRÜGGEMANN N. Novel NAXE variants as a cause for neurometabolic disorder: implications for treatment. J Neurol. 2020;267:770–782. doi: 10.1007/s00415-019-09640-2. PubMed DOI

Van DER AUWERA I, WERA S, Van LEUVEN F, HENDERSON ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s disease. Nutr Metab (Lond) 2005;2:28. doi: 10.1186/1743-7075-2-28. PubMed DOI PMC

VOET D, PRATT CW, VOET JG. Principles of Biochemistry. John Wiley & Sons, Inc; 2013.

WAN X, PEI H, ZHAO MJ, YANG S, HU WK, HE H, MA SQ, ZHANG G, DONG XY, CHEN C, WANG DW, LI B. Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy. Sci Rep. 2016;6:21587. doi: 10.1038/srep21587. PubMed DOI PMC

WANG D, GAO G. State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med. 2014;18:151–161. PubMed PMC

WEISSIG V. Drug development for the therapy of mitochondrial diseases. Trends Mol Med. 2020;26:40–57. doi: 10.1016/j.molmed.2019.09.002. PubMed DOI

WIJERMARS LG, SCHAAPHERDER AF, De VRIES DK, VERSCHUREN L, WÜST RC, KOSTIDIS S, MAYBORODA OA, PRINS F, RINGERS J, BIERAU J, BAKKER JA, KOOISTRA T, LINDEMAN JH. Defective postreperfusion metabolic recovery directly associates with incident delayed graft function. Kidney Int. 2016;90:181–191. doi: 10.1016/j.kint.2016.02.034. PubMed DOI

WU H, LI X, SHEN C. Peroxisome proliferator-activated receptor gamma in white and brown adipocyte regulation and differentiation. Physiol Res. 2020;69:759–773. doi: 10.33549/physiolres.934371. PubMed DOI PMC

YANG S, MA SQ, WAN X, HE H, PEI H, ZHAO MJ, CHEN C, WANG DW, DONG XY, YUAN JJ, LI B. Long-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy. EBioMedicine. 2016;10:258–268. doi: 10.1016/j.ebiom.2016.07.002. PubMed DOI PMC

YU-WAI-MAN P, GRIFFITHS PG, BROWN DT, HOWELL N, TURNBULL DM, CHINNERY PF. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet. 2003;72:333–339. doi: 10.1086/346066. PubMed DOI PMC

YU-WAI-MAN P, TURNBULL DM, CHINNERY PF. Leber hereditary optic neuropathy. J Med Genet. 2002;39:162–169. doi: 10.1136/jmg.39.3.162. PubMed DOI PMC

YUDKOFF M, DAIKHIN Y, MELØ TM, NISSIM I, SONNEWALD U, NISSIM I. The ketogenic diet and brain metabolism of amino acids: relationship to the anticonvulsant effect. Annu Rev Nutr. 2007;27:415–430. doi: 10.1146/annurev.nutr.27.061406.093722. PubMed DOI PMC

ZHANG J, LIU H, LUO S, LU Z, CHÁVEZ-BADIOLA A, LIU Z, YANG M, MERHI Z, SILBER SJ, MUNNÉ S, KONSTANTINIDIS M, WELLS D, TANG JJ, HUANG T. Live birth derived from oocyte spindle transfer to prevent mitochondrial disease. Reprod Biomed Online. 2017;34:361–368. doi: 10.1016/j.rbmo.2017.01.013. PubMed DOI

ZHANG Y, ZHOU S, ZHOU Y, YU L, ZHANG L, WANG Y. Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet. Epilepsy Res. 2018;145:163–168. doi: 10.1016/j.eplepsyres.2018.06.015. PubMed DOI

ZHAO K, ZHAO GM, WU D, SOONG Y, BIRK AV, SCHILLER PW, SZETO HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279:34682–34690. doi: 10.1074/jbc.M402999200. PubMed DOI

ZIAALDINI MM, HOSSEINI SR, FATHI M. Mitochondrial adaptations in aged skeletal muscle: effect of exercise training. Physiol Res. 2017;66:1–14. doi: 10.33549/physiolres.933329. PubMed DOI

Modern Perspective of Lactate Metabolism

Mitochondria in human reproduction: novel paradigm in the onset of neurodegenerative disorders

Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat